# JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）

> **NCT06505837** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 395 (actual)

## Conditions studied

- Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer

## Interventions

- **DRUG:** JS001sc (360mg Subcutaneous injection) and pemetrexed/platinum-containing chemotherapy
- **DRUG:** JS001 (240mg intravenous infusion) and pemetrexed/platinum-containing chemotherapy

## Key facts

- **NCT ID:** NCT06505837
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-11
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 395 (ACTUAL)
- **Last updated:** 2025-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06505837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06505837, "JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06505837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*